Understanding tuberculosis-associated COPD and its treatment
The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-associated Chronic Obstructive Pulmonary Disease in China: A Multicenter Prospective Cohort Study
This study is trying to understand the characteristics and best treatments for people with COPD linked to tuberculosis compared to those with regular COPD.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 540 (estimated) |
| Ages | 35 Years and up |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06074042 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the clinical characteristics, treatment approaches, and prognosis of patients with chronic obstructive pulmonary disease (COPD) associated with pulmonary tuberculosis. It will recruit two groups of participants: those with tuberculosis-associated COPD and those with non-tuberculosis associated COPD, across seven tertiary hospitals in mainland China. Participants will undergo a series of assessments, including demographic data collection, lung function tests, and follow-up evaluations every six months for one year to monitor the frequency of acute exacerbations. The study seeks to clarify the definition of this COPD phenotype and identify optimal pharmacologic interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are stable COPD patients aged 35 years or older with a history of pulmonary tuberculosis.
Not a fit: Patients with other obstructive pulmonary diseases, active tuberculosis, or severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients suffering from tuberculosis-associated COPD.
How similar studies have performed: While the concept of tuberculosis-associated COPD is recognized, this study addresses specific gaps in understanding and is considered a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who have dyspnea, chronic cough or sputum production and have definite airflow limitation with a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \<0.7; * in stable condition; * aged 35 years or older Exclusion Criteria: * bronchiectasis, asthma or any other obstructive pulmonary diseases; * pneumonia or active tuberculosis; * severe hepatic or renal insufficiency; * lung cancer or other advanced malignancies; * acquired immune deficiency due to HIV or chemotherapy; * severe trauma, operation or stress status in the past one month; * severe cognitive dysfunction; * unwilling to provide informed consent
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Ying Liang, M.D. — Peking University Third Hhospital
- Study coordinator: Ying Liang, M.D.
- Email: bysyliangying@126.com
- Phone: 86-01082266699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.